Fusion Non Operating Income Net Other vs Research Development Analysis

FUSN Stock

USD 21.52 0.03 0.14%

Fusion PharmaceuticalsI financial indicator trend analysis is much more than just examining Fusion PharmaceuticalsInc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fusion PharmaceuticalsInc is a good investment. Please check the relationship between Fusion PharmaceuticalsI Non Operating Income Net Other and its Research Development accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

Non Operating Income Net Other vs Research Development

Non Operating Income Net Other vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fusion PharmaceuticalsInc Non Operating Income Net Other account and Research Development. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Fusion PharmaceuticalsI's Non Operating Income Net Other and Research Development is 0.95. Overlapping area represents the amount of variation of Non Operating Income Net Other that can explain the historical movement of Research Development in the same time period over historical financial statements of Fusion PharmaceuticalsInc, assuming nothing else is changed. The correlation between historical values of Fusion PharmaceuticalsI's Non Operating Income Net Other and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Operating Income Net Other of Fusion PharmaceuticalsInc are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Non Operating Income Net Other i.e., Fusion PharmaceuticalsI's Non Operating Income Net Other and Research Development go up and down completely randomly.

Correlation Coefficient

0.95

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Non Operating Income Net Other

Research Development

Most indicators from Fusion PharmaceuticalsI's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fusion PharmaceuticalsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

At this time, Fusion PharmaceuticalsI's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 23rd of May 2024, Enterprise Value is likely to grow to about 649.9 M, though Tax Provision is likely to grow to (806.5 K).

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	634K	909K	1.2M	1.3M
Total Operating Expenses	83.5M	89.5M	100.0M	54.3M

Reconciled Depreciation Total Operating Expenses

Fusion PharmaceuticalsI fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Common Stock Shares Outstanding		0.24	0.35	0.32	0.11	0.16	0.09	0.3	-0.17	-0.3	0.21	0.53	0.11	0.17	0.01	0.28	0.27	0.57	0.19	-0.22	0.29	0.13	0.72	0.13	0.3	0.28
Total Assets	0.24		0.95	0.96	0.99	0.99	0.98	0.69	-0.19	-0.83	0.96	0.84	0.96	0.62	0.76	1.0	0.6	-0.58	0.97	-0.22	0.58	0.96	-0.35	0.99	0.69	1.0
Other Current Liab	0.35	0.95		1.0	0.91	0.94	0.89	0.77	0.04	-0.91	0.91	0.74	0.86	0.7	0.58	0.97	0.67	-0.41	0.98	-0.43	0.61	0.96	-0.15	0.94	0.77	0.96
Total Current Liabilities	0.32	0.96	1.0		0.93	0.95	0.91	0.78	0.03	-0.92	0.91	0.74	0.87	0.69	0.59	0.98	0.68	-0.45	0.99	-0.4	0.62	0.97	-0.2	0.95	0.78	0.98
Total Stockholder Equity	0.11	0.99	0.91	0.93		0.99	1.0	0.64	-0.22	-0.78	0.95	0.8	0.97	0.63	0.79	0.98	0.53	-0.7	0.96	-0.13	0.52	0.95	-0.49	1.0	0.63	0.98
Other Liab	0.16	0.99	0.94	0.95	0.99		0.98	0.63	-0.21	-0.79	0.97	0.82	0.98	0.62	0.8	0.98	0.56	-0.62	0.97	-0.23	0.52	0.95	-0.4	0.99	0.63	0.98
Net Tangible Assets	0.09	0.98	0.89	0.91	1.0	0.98		0.58	-0.26	-0.74	0.96	0.79	0.97	0.66	0.8	0.96	0.47	-0.72	0.95	-0.08	0.46	0.93	-0.52	0.99	0.58	0.96
Property Plant And Equipment Net	0.3	0.69	0.77	0.78	0.64	0.63	0.58		0.43	-0.96	0.55	0.47	0.53	0.26	0.24	0.73	0.96	-0.23	0.72	-0.64	0.94	0.77	-0.04	0.67	1.0	0.73
Net Debt	-0.17	-0.19	0.04	0.03	-0.22	-0.21	-0.26	0.43		-0.34	-0.27	-0.55	-0.36	-0.04	-0.6	-0.13	0.45	0.2	-0.02	-0.67	0.35	0.06	0.22	-0.16	0.45	-0.14
Retained Earnings	-0.3	-0.83	-0.91	-0.92	-0.78	-0.79	-0.74	-0.96	-0.34		-0.74	-0.57	-0.69	-0.48	-0.38	-0.87	-0.89	0.32	-0.87	0.62	-0.84	-0.9	0.1	-0.82	-0.96	-0.86
Accounts Payable	0.21	0.96	0.91	0.91	0.95	0.97	0.96	0.55	-0.27	-0.74		0.84	0.97	0.69	0.83	0.95	0.47	-0.59	0.92	-0.2	0.42	0.88	-0.38	0.95	0.55	0.94
Cash	0.53	0.84	0.74	0.74	0.8	0.82	0.79	0.47	-0.55	-0.57	0.84		0.86	0.35	0.84	0.82	0.45	-0.29	0.71	-0.1	0.48	0.67	-0.1	0.78	0.47	0.82
Non Current Assets Total	0.11	0.96	0.86	0.87	0.97	0.98	0.97	0.53	-0.36	-0.69	0.97	0.86		0.55	0.9	0.93	0.47	-0.67	0.9	-0.13	0.45	0.88	-0.48	0.96	0.52	0.93
Non Currrent Assets Other	0.17	0.62	0.7	0.69	0.63	0.62	0.66	0.26	-0.04	-0.48	0.69	0.35	0.55		0.27	0.64	0.04	-0.42	0.7	0.06	-0.06	0.63	-0.25	0.63	0.26	0.63
Other Assets	0.01	0.76	0.58	0.59	0.79	0.8	0.8	0.24	-0.6	-0.38	0.83	0.84	0.9	0.27		0.7	0.26	-0.61	0.63	0.01	0.28	0.6	-0.5	0.76	0.24	0.7
Cash And Short Term Investments	0.28	1.0	0.97	0.98	0.98	0.98	0.96	0.73	-0.13	-0.87	0.95	0.82	0.93	0.64	0.7		0.63	-0.53	0.98	-0.27	0.6	0.97	-0.3	0.99	0.73	1.0
Net Receivables	0.27	0.6	0.67	0.68	0.53	0.56	0.47	0.96	0.45	-0.89	0.47	0.45	0.47	0.04	0.26	0.63		-0.12	0.61	-0.77	0.98	0.67	0.05	0.58	0.96	0.63
Non Current Liabilities Total	0.57	-0.58	-0.41	-0.45	-0.7	-0.62	-0.72	-0.23	0.2	0.32	-0.59	-0.29	-0.67	-0.42	-0.61	-0.53	-0.12		-0.57	-0.26	-0.12	-0.58	0.96	-0.66	-0.21	-0.54
Capital Surpluse	0.19	0.97	0.98	0.99	0.96	0.97	0.95	0.72	-0.02	-0.87	0.92	0.71	0.9	0.7	0.63	0.98	0.61	-0.57		-0.3	0.56	0.99	-0.33	0.98	0.72	0.98
Inventory	-0.22	-0.22	-0.43	-0.4	-0.13	-0.23	-0.08	-0.64	-0.67	0.62	-0.2	-0.1	-0.13	0.06	0.01	-0.27	-0.77	-0.26	-0.3		-0.66	-0.35	-0.39	-0.21	-0.67	-0.25
Other Current Assets	0.29	0.58	0.61	0.62	0.52	0.52	0.46	0.94	0.35	-0.84	0.42	0.48	0.45	-0.06	0.28	0.6	0.98	-0.12	0.56	-0.66		0.63	0.02	0.55	0.94	0.61
Other Stockholder Equity	0.13	0.96	0.96	0.97	0.95	0.95	0.93	0.77	0.06	-0.9	0.88	0.67	0.88	0.63	0.6	0.97	0.67	-0.58	0.99	-0.35	0.63		-0.35	0.97	0.77	0.97
Total Liab	0.72	-0.35	-0.15	-0.2	-0.49	-0.4	-0.52	-0.04	0.22	0.1	-0.38	-0.1	-0.48	-0.25	-0.5	-0.3	0.05	0.96	-0.33	-0.39	0.02	-0.35		-0.44	-0.02	-0.31
Net Invested Capital	0.13	0.99	0.94	0.95	1.0	0.99	0.99	0.67	-0.16	-0.82	0.95	0.78	0.96	0.63	0.76	0.99	0.58	-0.66	0.98	-0.21	0.55	0.97	-0.44		0.67	0.99
Property Plant And Equipment Gross	0.3	0.69	0.77	0.78	0.63	0.63	0.58	1.0	0.45	-0.96	0.55	0.47	0.52	0.26	0.24	0.73	0.96	-0.21	0.72	-0.67	0.94	0.77	-0.02	0.67		0.73
Total Current Assets	0.28	1.0	0.96	0.98	0.98	0.98	0.96	0.73	-0.14	-0.86	0.94	0.82	0.93	0.63	0.7	1.0	0.63	-0.54	0.98	-0.25	0.61	0.97	-0.31	0.99	0.73

Click cells to compare fundamentals

Fusion PharmaceuticalsI Account Relationship Matchups

Fusion PharmaceuticalsI fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	155.7M	22.0M	42.6M	43.7M	65.6M	57.7M
Total Assets	69.4M	310.7M	252.3M	219.1M	285.8M	214.3M
Other Current Liab	3.4M	7.5M	7.6M	10.0M	9.9M	7.3M
Total Current Liabilities	4.3M	11.9M	12.5M	15.1M	16.2M	11.3M
Total Stockholder Equity	(33.5M)	294.5M	231.5M	162.2M	222.5M	157.5M
Other Liab	321K	4.3M	2.8M	3.0M	3.4M	2.3M
Net Tangible Assets	(33.5M)	294.5M	231.5M	162.2M	186.6M	140.1M
Property Plant And Equipment Net	1.3M	2.0M	9.5M	10.3M	23.9M	25.1M
Net Debt	(59.6M)	(90.5M)	(46.2M)	(3.6M)	(11.6M)	(12.2M)
Retained Earnings	(34.8M)	(113.2M)	(194.3M)	(281.9M)	(376.8M)	(357.9M)
Accounts Payable	830K	3.4M	2.2M	2.7M	1.9M	2.1M
Cash	65.3M	90.5M	52.9M	43.9M	61.9M	62.9M
Non Current Assets Total	2.8M	82.5M	40.5M	40.1M	42.4M	38.4M
Non Currrent Assets Other	1.5M	2.8M	9.4M	9.2M	849K	806.6K
Other Assets	1.6M	80.5M	11.1M	14.0M	16.1M	23.6M
Cash And Short Term Investments	65.3M	222.4M	200.8M	186.6M	234.1M	172.0M
Net Receivables	428K	794K	357K	1.7M	4.2M	4.4M
Liabilities And Stockholders Equity	69.4M	310.7M	252.3M	219.1M	285.8M	214.3M
Non Current Liabilities Total	98.6M	4.3M	8.3M	41.8M	47.1M	33.0M
Capital Surpluse	1.3M	407.7M	425.8M	444.6M	511.2M	281.6M
Inventory	503K	4.2M	10.4M	(9.9M)	(8.9M)	(8.4M)
Other Current Assets	278K	727K	233K	509K	5.1M	5.4M
Other Stockholder Equity	(70.3M)	407.7M	425.8M	444.6M	599.0M	331.4M
Total Liab	102.9M	16.2M	20.8M	56.8M	63.4M	41.2M
Net Invested Capital	(33.5M)	294.5M	231.5M	196.5M	257.3M	170.2M
Property Plant And Equipment Gross	1.3M	2.0M	9.5M	12.3M	26.4M	27.7M
Total Current Assets	66.6M	228.2M	211.8M	179.0M	243.4M	175.8M
Accumulated Other Comprehensive Income	(428K)	44K	(115K)	(469K)	237K	248.9K
Net Working Capital	62.3M	216.3M	199.3M	163.9M	227.2M	164.6M
Property Plant Equipment	1.3M	2.0M	3.0M	4.6M	5.3M	5.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Fusion PharmaceuticalsInc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fusion PharmaceuticalsI's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fusion Pharmaceuticalsinc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fusion Pharmaceuticalsinc Stock:

How To Invest In Fusion

Details

Is Fusion Stock a good investment?

Details

What is Fusion PharmaceuticalsI's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Fusion Stock analysis

When running Fusion PharmaceuticalsI's price analysis, check to measure Fusion PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fusion PharmaceuticalsI is operating at the current time. Most of Fusion PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Fusion PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fusion PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Fusion PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.

	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Stocks Directory Find actively traded stocks across global markets
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Global Correlations Find global opportunities by holding instruments from different markets
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity

Is Fusion PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion PharmaceuticalsI. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.40)

Revenue Per Share

0.028

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.23)

Return On Equity

(0.47)

The market value of Fusion PharmaceuticalsInc is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Fusion PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Fusion PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Fusion PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Fusion Non Operating Income Net Other vs Research Development Analysis

Non Operating Income Net Other vs Research Development

Non Operating Income Net Other vs Research Development Correlation Analysis

Correlation Coefficient

Non Operating Income Net Other

Research Development

Fusion PharmaceuticalsI fundamental ratios Correlations

Fusion PharmaceuticalsI Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Fusion PharmaceuticalsI fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Fusion Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Property Plant And Equipment Gross	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net
Retained Earnings	- 0.92	Total Current Liabilities
Retained Earnings	- 0.91	Other Current Liab
Other Stockholder Equity	- 0.9	Retained Earnings
Net Receivables	- 0.89	Retained Earnings